BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Journal of Clinical Oncology, 05/24/2012
Colombino M et al. – In the era of targeted therapies, assessment of the spectrum and distribution of alterations in molecular targets among patients with melanoma is needed. The findings about the prevalence of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful in the management of this disease.